A phase I study of vernakalant (Brinavess) in healthy volunteers

Trial Profile

A phase I study of vernakalant (Brinavess) in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2016 Status changed from planning to recruiting according to Cardiome Pharma media release.
    • 29 Jul 2015 New trial record
    • 24 Jul 2015 According to a Cardiome Pharma media release, this study will support the regulatory approval of vernakalant [BRINAVESS] in China. If BRINAVESS successfully completes Phase I, Eddingpharm anticipates initiating a pivotal Phase 3 study by year end.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top